Recombinant B-Cell CLL/Lymphoma 10 (Bcl10)
Cat#:TP01310应用:Positive Control; Immunogen; SDS-PAGE; WB
Product Name: | Bcl10 Rabbit pAb |
Cat No.: | DPA01687 |
Clonality: | Polyclonal |
Species Reactivity: | Human |
Tested Applications: | WB,FC |
Recommended Dilution: | WB: 1:1000 FC: 1:100-1:500 |
Size: | 30ul 50ul 100uL |
Format: | Liquid |
Source: | Rabbit |
Purification Method: | Affinity Purification |
Isotype: | IgG |
Conjugate: | Un-conjugated |
Storage: | Store at -20°C. Supplied in 50nM Tris-Glycine(pH 7.4), 0.15M NaCl, 40%Glycerol, 0.01% sodium azide a |
Immunogen: | A synthetic peptide of human Bcl10 |
Calculated Molecular Weight: | 26 kDa |
Observed Molecular Weight: | 26 kDa |
GenBank Accession Number: | O95999 |
Gene ID (NCBI): | 8915 |
Synonyms: | CLAP; mE10; CIPER; IMD37; c-E10; CARMEN |
Background: | This gene was identified by its translocation in a case of mucosa-associated lymphoid tissue (MALT) lymphoma. The protein encoded by this gene contains a caspase recruitment domain (CARD), and has been shown to induce apoptosis and to activate NF-kappaB. This protein is reported to interact with other CARD domain containing proteins including CARD9, 10, 11 and 14, which are thought to function as upstream regulators in NF-kappaB signaling. This protein is found to form a complex with MALT1, a protein encoded by another gene known to be translocated in MALT lymphoma. MALT1 and this protein are thought to synergize in the activation of NF-kappaB, and the deregulation of either of them may contribute to the same pathogenetic process that leads to the malignancy. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Mar 2016] |
Category: | Primary Ab |